Knight Total Stockholder Equity from 2010 to 2024

GUD Stock  CAD 5.29  0.01  0.19%   
Knight Therapeutics Total Stockholder Equity yearly trend continues to be very stable with very little volatility. Total Stockholder Equity is likely to grow to about 823.4 M this year. Total Stockholder Equity is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. View All Fundamentals
 
Total Stockholder Equity  
First Reported
2013-09-30
Previous Quarter
761.9 M
Current Value
762.8 M
Quarterly Volatility
248.9 M
 
Yuan Drop
 
Covid
Check Knight Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Knight Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 52.9 M, Interest Expense of 9.4 M or Selling General Administrative of 23.9 M, as well as many indicators such as Price To Sales Ratio of 1.61, Dividend Yield of 0.5 or PTB Ratio of 0.71. Knight financial statements analysis is a perfect complement when working with Knight Therapeutics Valuation or Volatility modules.
  
This module can also supplement various Knight Therapeutics Technical models . Check out the analysis of Knight Therapeutics Correlation against competitors.

Pair Trading with Knight Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Knight Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Knight Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Knight Stock

  0.69TD-PFI Toronto Dominion BankPairCorr
  0.66FTN-PA Financial 15 SplitPairCorr
  0.64NVDA NVIDIA CDRPairCorr
  0.63FFH Fairfax FinancialPairCorr
  0.57FSV FirstService CorpPairCorr
The ability to find closely correlated positions to Knight Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Knight Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Knight Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Knight Therapeutics to buy it.
The correlation of Knight Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Knight Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Knight Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Knight Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in Knight Stock

Knight Therapeutics financial ratios help investors to determine whether Knight Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Knight with respect to the benefits of owning Knight Therapeutics security.